Sputnik V vaccine. Photo: Gamaleya National Center of Epidemiology and Microbiology
A study published in medical journal The Lancet states that Russia’s Sputnik V vaccine has a 91.6-percent efficacy rate against the coronavirus. Brazilian federal regulators, however, says the data relates to a different vaccine from that which is attempting clearance for emergency use in Brazil.
The agency says the results published in The Lancet relate to liquid vaccines stored at -18 degrees Celsius, while the Brazilian producers of Sputnik V propose different temperature and storage conditions.
União Química, the local producer of Sputnik V, has been called out by regulators for its slow pace in responding to information requests. The pharmaceutical group has yet to provide reports on late-stage clinical trial data proving efficacy rates of at least 50 percent.
The Mexican government has cleared the Russian vaccine for emergency use. It will be the third immunizer to be used in the country, following those by Pfizer and AstraZeneca. Hugo López Gatell, Mexico’s deputy health secretary, says 400,000 doses are expected to arrive “in a matter of days.”
Support this coverage →Panama was once a part of Colombia. Its canal, a monumental engineering achievement of its…
The specialization trend among corporate board members It is not only a matter of perception:…
Panama will hold its presidential elections on Sunday, months after huge protests saw thousands descend…
The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…